Innovafeed raises €51M to scale insect protein commercialisation
What's the deal? French insect protein producer Innovafeed has closed a €51M (~$55.1M) funding round, marking its shift from industrial R&D to full-scale commercial deployment. The company will use the capital to accelerate sales of its Hilucia™ product line across aquaculture, pet food, and sustainable agriculture markets, with its flagship facility in Nesle, France, serving as the hub for global expansion.
Over three years, the Nesle site produced more than 15,000 tons of high-grade protein and oil. Production volumes grew tenfold, while unit manufacturing costs dropped by a factor of seven.
Why now? Innovafeed says it has reached full operational maturity at Nesle — a milestone that makes further heavy investment in zootechnical R&D unnecessary. The company is consolidating operations from its historical research site in Gouzeaucourt into Nesle, a move that includes cutting 60 positions, two-thirds of them at Gouzeaucourt.
Management said the restructuring is being carried out with dedicated employee support frameworks and in coordination with its Social and Economic Committee and national regulators.
The timing also reflects growing demand. Long-term partnerships with global clients in aquaculture and pet care are driving commercial traction. Fabio Brambilla, a nutritionist at NaturAlleva, called Innovafeed's technology "the most advanced in Europe" and said his company plans to use the ingredients "on a very broad scale" for sea bass, sea bream, and trout feed.
What could go wrong? Insect protein remains a niche ingredient competing against entrenched alternatives like fishmeal and soy. Scaling commercial adoption across diverse geographies and regulatory environments is no small feat — even with a cost base that has improved dramatically.
The 60-job reduction also underscores a tension common in deep-tech scaleups: the transition from research to commercialisation often means the people who built the technology are no longer the ones needed to sell it.
The signal: Innovafeed sits at the late growth stage, according to Dealroom, a classification that aligns with its pivot from R&D-heavy capital expenditure to commercialisation-driven revenue growth. The €51M round — raised without the backing of a marquee venture lead — suggests the company is financing expansion from a position of operational proof rather than speculative promise, a pattern increasingly common among European deep-tech scaleups that have survived the funding downturn by demonstrating unit economics before seeking fresh capital.
